tradingkey.logo

Bristol-Myers Squibb Co

BMY
View Detailed Chart
43.755USD
+0.165+0.38%
Market hours ETQuotes delayed by 15 min
89.04BMarket Cap
17.64P/E TTM

Bristol-Myers Squibb Co

43.755
+0.165+0.38%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.38%

5 Days

+0.49%

1 Month

-2.81%

6 Months

-11.12%

Year to Date

-22.64%

1 Year

-17.78%

View Detailed Chart

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bristol-Myers Squibb Co's Score

Industry at a Glance

Industry Ranking
41 / 173
Overall Ranking
104 / 4689
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 29 analysts
Hold
Current Rating
51.633
Target Price
+18.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bristol-Myers Squibb Co Highlights

StrengthsRisks
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is 17.50, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.69B shares, decreasing 1.01% quarter-over-quarter.
Held by Irving Kahn
Star Investor Irving Kahn holds 550.68K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Bristol-Myers Squibb Co Info

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.
Ticker SymbolBMY
CompanyBristol-Myers Squibb Co
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Websitehttps://www.bms.com
KeyAI